Ajanta Pharma Limited (AJANTPHARM) Earnings Call Transcript & Summary

Ladies and gentlemen, good day, and welcome to Ajanta Pharma Q4 FY '25 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Yogesh Agrawal, Managing Director of Ajanta Pharma Limited. Thank you, and over to you, sir.

Thank you. Good evening, and welcome to all of you. With me, I have Mr. Rajesh Agrawal, our Joint Managing Director; Mr. Arvind Agrawal, Chief Finance Officer; and Mr. Rajeev Agarwal, our AVP, Finance and Investor Relations. The results are already with you. We will take you through business-wise performance for the quarter and for the whole year, along with the comparison of previous year same period. Let's get into the business performance. For the current year, FY 2025 marked yet another year of outstanding performance, driven by our well-crafted strategy and strong operational execution. We are committed to growing sustainably and scaling up responsibly, building every part of the business in such a manner that creates long-term value to our stakeholders. Staying true to our commitment of growing the branded generic business in mid-teens, I am pleased to share that we delivered a healthy growth of 15% during the year. Our financial strength also continued to improve with ROCE at 32% and return on net worth reaching 25% as of March 2025, reinforcing our position amongst the best in the industry. Our strong cash conversion ratio of 92% enabled us to distribute a significant payout of INR 700 crores to our shareholders, reaffirming our commitment to delivering value to our stakeholders. Moving on to the business details. Our overall business saw a healthy growth of 11% during the quarter and 10% for the year in spite of sharp degrowth in Africa institution business and soft growth in U.S. generic business. The growth for the year was fueled by an excellent performance of our branded generic business, which contributed 74% in overall revenue. This business is spread across India, Asia and Africa. The sales stood at INR 805 crores during the quarter, posting 12% growth and INR 3,394 crores, a growth of 15% during the year. This business exhibits assurance, sustainability and scalability in the long run. Let me now take up international business, and I will first start with branded generic business in Asia and Africa, which contributed 42% in the total revenue. Let's begin with Asia. Ajanta's Asia business extends across Middle East, Southeast Asia and Central Asia, covering nearly 10 countries. We are strategically strengthening this business through increased investment in both products and people to drive accelerated growth in the coming years. I am pleased to share that we have significantly expanded our product portfolio in the region with launch of 25 new products, primarily in chronic therapies. This expansion positions us strongly for the sustained growth in FY 2026 and beyond. In Q4, sale was INR 303 crores against INR 281 crores, a growth of 8%. And during the year FY 2025, sale was at INR 1,191 crores against INR 1,057 crores, a healthy growth of 13%. Let's move to Africa. In FY 2025, our Africa business achieved an outstanding growth of 28%, driven by continued strategic focus on expanding our chronic therapies portfolio in the region and successful launch of 13 new products. These initiatives are steadily building a strong foundation for more sustainable and scalable business in the years to come. As we look ahead, while the Africa pharma market is anticipated to witness a moderation in growth in FY 2026, alongside the impact of high base effect FY 2025 for Ajanta, we remain confident in the long-term potential and strength of our business in the region. During the quarter, the sale was INR 133 crores against INR 113 crores, a growth of 17%. And for the year, sale was INR 750 crores against INR 585 crores, a healthy growth of 28%. Let us talk about other 2 verticals of international business now. Let's go with U.S. Generics. As anticipated, our U.S. generic business closed the year with a growth of 9%, with all 5 new product launches occurring in the second half of the year, limiting their ability to contribute to the full year performance. However, we are well positioned to capture the complete potential of this product in FY 2026, which is expected to witness a stronger growth, supported by a robust pipeline of additional launches planned for the year. We remain vigilant considering ongoing tariff uncertainties and will respond based on actual outcome. During the quarter, the sale was INR 325 crores against INR 261 crores, posting a healthy growth of 25%. And for the year, the sale was INR 1,047 crores against INR 964 crores, a growth of 9%. Our superior execution continues to keep us as a preferred partner of choice for the distributors. Let's go -- let's move to the Africa institution. As we have consistently highlighted over the years, this business has remained unpredictable due to its heavy dependence on the procurement agencies. During the year, the business experienced a significant degrowth of 41%, including a sharper decline of 53% during the Q4, reducing its contribution to the revenue to just 3%. Consequently, it has become a very small part of our overall business. Looking ahead, we continue to maintain a cautious outlook on this segment for the foreseeable future. The Antimalarial business contributed a revenue of INR 147 crores during the year against INR 249 crores in the previous year. Revenue for the quarter was INR 28 crores against INR 61 crores. Now I invite Mr. Rajesh Agrawal, our Joint Managing Director, to take you through India business. Thank you, and over to you.

Thank you, and good evening to all of you. FY 2025 was indeed an eventful year for the India business with many new initiatives. First, there was the addition of 2 new therapies, gynecology and nephrology with a little over 200 MRs in the domestic market. Secondly, there is a significant expansion that we undertook in the existing therapies with addition of 250 new MRs, and we are open for further expansion in the FY 2026 as may be necessary. And third, acquisition of 3 brands in the Pain Management segment. I am pleased to share that as a part of the strategic initiatives, we have taken a significant step forward with the first-ever acquisition of 3 brands in the Pain Management segment. These additions align well with the accelerated growth trajectory of our India business and will further strengthen our pain portfolio. It is important to note that the value of these brands fall below the threshold for mandatory disclosure. We continue to outperform the Indian pharmaceutical market by a significant margin of 300 basis points for the year, with Ajanta delivering an impressive growth of 11% compared to IPM's 8% growth. Notably, our volume was nearly double of the IPM. This positive trend is evident across most therapeutic segments, in which we operate, where our growth was consistently outpaced -- has consistently outpaced segment averages. We remain confident of sustaining this momentum in the coming years, backed by a robust pipeline of new product launches. Focusing on our performance in FY 2025, the India business contributed 32% to the company's total revenue, supported by the launch of 32 new products, including 8 first-time launches in the country. In Q4, sales stood at INR 369 crores compared to INR 326 crores in the same quarter of the previous year, registering a healthy growth of 13%. For FY 2025, sales reached INR 1,452 crores, up from INR 1,308 crores in FY 2024, reflecting a growth of 11%. Our India business also includes revenue from the trade generics segment, which contributed INR 49 crores in Q4, up from INR 41 crores and INR 179 crores for the full year compared to INR 161 crores in FY 2024. In the covered market, we are fifth largest in IPM and among top 10 in all our therapeutic segments. As per IQVIA MAT March 2025, cardiology contributed 38%, followed by ophthalmology 29%, dermatology 23% with remaining 10% coming from pain in India branded sales. I now invite Arvind Agrawal, CFO, to take you through the financial performance. Thank you, and over to you, Arvind ji.

Thank you. Good evening, and warm welcome to the fourth earnings call of FY 2025. On this call, our discussion includes certain forward-looking statements, which are projections or estimates about future events. These estimates reflect management's current expectations about future performance of the company. These estimates involve a number of risks and uncertainties that could cause our actual results to differ materially from what is expressed or implied. Ajanta does not undertake any obligations to publicly update any forward-looking statements, whether because of new confirmation, future events or otherwise. We will look at the consolidated financials and provide year-on-year comparison. The key financial highlights of Q4 and FY 2025 are as follows. Total revenue in Q4 stood at INR 1,170 crores against INR 1,054 crores, posting growth of 11%. For FY 2025, the revenue was INR 4,648 crores against INR 4,209 crores, posting growth of 10%, which was in line with our guidance. Our gross margin stood at 77% in FY 2025, an improvement of 200 basis points over previous year. This was a result of higher contribution from branded generic business in overall revenue. We expect it to remain in the similar range with movement of 50 to 100 basis points due to change in product mix. For FY 2025, personnel cost stood at INR 1,090 crores, an increase of 21% over previous year. Change in gratuity policy in Q1 and addition of medical representatives in India has resulted in this exceptional increase. We expect this to get normalized in FY 2026. In Q4, the cost was at INR 280 crores, an increase of 20%. Our R&D spend continues to be at 5% of total revenue and expected to remain at similar level going ahead. In Q4, expenses were INR 63 crores against INR 50 crores. And in FY 2025, it was INR 224 crores against INR 208 crores. Other expenses in Q4 stood at INR 310 crores against INR 278 crores and in FY 2025, it was at INR 1,228 crores against INR 1,070 crores previous year same period. Our thrust on the branded generic business with investment in products and people will keep other expenses elevated in FY '26 as well. Our EBITDA margin stood at 27% for FY 2025, though it was lower at 25% in Q4 due to higher personnel costs and lower gross margin for change in business mix. EBITDA stood at INR 297 crores against INR 278 crores, a growth of 7% in Q4 and INR 1,260 crores against INR 1,172 crores, a growth of 7% in FY 2025 over previous year. We expect the EBITDA in FY 2026 to be around FY 2025 range. Other income was at INR 18 crores in Q4 and INR 95 crores in FY 2025. It includes ForEx gain of INR 7 crores and INR 28 crores, respectively, in Q4 and 12 months. Income tax stood at 23% of the FY 2025 and is expected to remain at this level in FY 2026. In Q4, PAT was INR 225 crores against INR 203 crores, a growth of 11%. And for FY 2025, it was INR 920 crores against INR 816 crores, a growth of 13%. PAT stood at 19% in Q4 and 20% for FY 2025. CapEx was a little higher for the year with investment of INR 318 crores in FY 2025. This includes new liquid plant at Pithampur, new office in Andheri and brand acquisition cost. CapEx, including maintenance CapEx for FY 2026 is estimated to be around INR 300 crores. Working capital remained our focus area, and we will continue to monitor it closely. Trade receivables at 94 days against 109 days and inventory at 72 days against 73 days is becoming a normal level. Our cash flow from operations at INR 1,157 crores for FY 2025 is indeed a landmark with cash conversion ratio of 92%. Free cash flow of INR 694 crores with 75% PAT conversion also reflects our efficient cash flow management. ROCE and RONW continue to improve and be comparable to the best in the industry. ROCE stands at 32% and RONW at 25% at the end of March 2025. With these highlights, I open the floor for the question and answer. Thank you.

[Operator Instructions] First question is from the line of Tushar Manudhane from Motilal Oswal Financial Services.

Sir, just a clarification on this EBITDA margin guidance, you said similar to that of FY '25, right?

Yes.

28% plus/minus, correct?

Sorry?

28% plus...

Can you repeat your question?

Sir, just a clarification on EBITDA margin guidance first for FY '26?

Yes.

So you highlighted...

28% plus/minus 1%.

Got it. So but given the kind of growth which we are witnessing in the branded generics business, and still, if you are guiding for a similar EBITDA margin, so does it mean that other expenses are going to further rise from here on?

Yes, to some extent because the investment which we have done in people, et cetera, is going to increase the sales and promotion cost...

This is...

Because in the current year, 450 people have been added over a period of second, third quarter. So naturally, their full cost will come in this year.

And sir, gross margin lower is largely to do with U.S. exposure higher...

On a quarter, yes, you are right.

And then subsequently, we are guiding for the gross margin also to be broadly similar as that of 4Q or FY '25?

FY '25.

Next question is from the line of Vishal from Systematix.

In the presentation, you've shown that the ophthalmology segment has grown only 5% this year. So any specific reason the segment growth was lower this year?

Yes. Yes. No, there is no specific reason. I mean, nothing that we can point out. It's -- that's what it is.

Okay. And so the next one is like you have INR 176 crores in capital work in progress. Would you be able to share what that pertains to?

It pertains to various projects which we are undertaking, the head office, which is the Ajanta Tower, which is going on at the moment. Some of the floors are yet to be completed and capitalized, plus also we have our liquid plant Pithampur...

Ladies and gentlemen, the line for the management has been disconnected. Please stay connected, while we reconnect them to the call. Ladies and gentlemen, thank you for patiently holding. We have the line for the management reconnected. Over to you, sir.

Yes. Vishal, you were asking something.

There was a technical glitch.

Yes, sir. I was asking about the CWIP, which you indicated part of it is on account of Ajanta Tower and the rest you were talking about a liquid plant, which -- and then it got disconnected.

Yes. So it is a liquid plant in Pithampur, which we are setting up. So that is there, plus also some other small projects which are going on in different manufacturing sites.

Okay. So this liquid plant pertains to the U.S. markets or the India market?

No. No. This is for the emerging markets.

Okay. Okay. And sir, one question on this U.S. market. So you have a product called Oxtellar XR, where you are the third generic, which has an approval, but what I could see is you have discontinued the product on the site. Is any reason to discontinue that product?

No, no. There is no -- which website you're talking about?

So on Drugs@FDA, what I can see is Apotex and one more player have launched the drug, but Ajanta, which also has an approval, but it's showing discontinued there.

Yes. No, I don't know. We'll have to see the website what is showing. We have not discontinued. In fact, we have launched that product in the last quarter as an authorized generic from the Supernus from the originator...

Okay. So since it is an authorized generic, would that be the reason to have discontinued your own ANDA?

No, no. We will be going to be transitioning into our ANDA. Once our AG contract time expires with Supernus, then we will transition into our own ANDA. We will have to -- I will have to check what website you're talking of. We are not aware of that. As far as we are concerned, we have approval for that. Right now, we have launched as authorized generic. And once that time line is over, then we will be coming with our own product -- we'll be launching our own product.

And what would be our market share as an authorized generic there now in Oxtellar XR?

Right now, it is small because we just launched recently last quarter. But going forward, I think we will be able to increase our market share.

Okay. Understood. And just a follow-up on the ophthalmology slowdown. Just wanted to understand whether the segment is largely driven by cataract surgeries and chronic areas like glaucoma and dry eye and whether Ajanta has a strong presence in these segments?

Yes. We have a presence in more than 80% of the subtherapeutic areas. Dry eye is also post-cataract anti-infectives, anti-allergics, glaucoma. So we are present largely into all of these NSAIDs for ophthalmology. And as far as the growth rate is concerned, there are many other segments like, for example, gynecology has grown only at 4%. Respiratory has grown, again, mid-single digit. So there are multiple, and that's why you see the IPM growing only at 8%. There is no specific reason. I think that's a question for IQVIA to maybe look into an answer.

But on a reported basis also, you would have grown slower in ophthalmology or -- because this is secondary data, but for you on a primary basis -- like primary sales to the channel, would you have grown at mid-single digit or higher rates?

We are at mid-single. IQVIA data, we have grown at 6% compared to the market growth of 5%. So that is what is most relevant for us.

[Operator Instructions] Next question is from the line of Abdulkader Puranwala from ICICI Securities.

Sir, first question is in relation to your India business so that you have added a few MRs this year. And what would be the quantum of MR addition for the next year?

Your voice is not -- we don't have a specific objective for adding any numbers. We will optimize the field strength as we go along wherever we feel that additions are required. It's just start of the year. We will know after maybe first quarter as to where all and how we add the MRs in which segment and in which territories. So there is no specific number that we are starting the year with.

Okay. Okay. And sir, when we talked about last quarter and this quarter as well about foraying into 2 new therapeutic categories, just wanted to understand from a prescriber standpoint, so the MRs are currently catering to the same prescribers. And the reason why I'm asking that if I look at your presentation, then the doctor coverage kind of stands flat at 2.5 lakh doctors, if we check that with the previous quarter presentation as well. So can you throw some light there, please?

Yes. No, you're right. The reason being in nephrology segment, it's a very small subset of the frank nephrologists by way of qualification. It's an insignificant number to be really to see an impact on the 2.5 lakh odd doctors that we cover. And it's a relatively smaller field force. It's more of a task force-based approach. We were already covering nephrologists by way of our existing brands, which are Feburic and Cinod, which are also heavily prescribed by nephrologist. And it's the same customer, but we are having a first-line treatment products through the nephro team now. Therefore, even those minor additions are already factored in by nephrology. In Gynic, we have a small team at this point. So the coverage is not massive all India. We hope to be able to expand the footprint, as we go along in the coming year. So you may see some attrition in the doctor coverage by the end of the year to be more specific on that. But already in our investor presentation, it's mentioned as 2.5 lakh plus. So if there are minor additions, that will cover that.

Understood. Understood. And one more on your Africa Institution business. I know that you have been quite cautious on the outlook of this business for quite some time. But given the recent uncertainties about donor funding, though not directly related to your line of business, but any outlook you may like to provide on that front would be helpful.

No. As you have seen in current year also, we have degrown heavily. And -- so this is one business segment we can never give a guidance on. We don't know what kind of procurements will be done by the agencies, what kind of money they will be getting. Now with the U.S. aid, U.S. government has said that they are not -- don't want to continue with U.S. aid anymore. We're not sure what kind of procurements they will do if at all, they will do anything. So I think this segment of the business continues to remain unpredictable. The best thing we can do is we can -- whenever opportunity comes, we can maximize it. So there is no guidance which we have for this segment or no outlook.

Okay. Got it. And just final one, if I may. Any revenue growth guidance you would like to provide for your branded generic and U.S. business for next year?

So U.S. business, we are looking to mid- to high teens kind of growth. And for the branded generic, low teens -- we are looking at low teens.

[Operator Instructions] next question is from the line of Foram Parekh from Bank of Baroda Capital Markets.

Can you highlight on the outlook of ANDA filings in FY '26, please?

We are looking at filing around 10 to 12 ANDAs in the '25, '26.

Okay. And can you just comment on the U.S. tariff, if implemented? So how are we seeing this? How much would it -- I mean, how would it impact us? Do I understand the portion -- or the contribution from the U.S. side is very small for us. But just an overall broader perspective, how are you seeing the tariff if levy would impact us?

So as you may be aware, which is announced by the U.S. government, they have initiated a Section 232 investigation, which means the U.S. government had initiated a study that if at all, what kind of imports they are doing for the pharmaceutical products in the U.S. And for -- if any reason, if they're doing substantial import, those countries do not supply to U.S., what is at risk? And then they have to come out with the mitigation strategy for that. So they have announced this study. This study can get completed in 90 days or 270 days. We don't know what the outcome will be. It's a very complex and convoluted situation where there are -- India is one of the large exporter of pharmaceutical products to U.S. At the same time, building such capacities in U.S., if at all, they were to be built, it's a long process. So I think there is no clarity on what kind of tariffs, if at all, they will come. So far, they have been exempted. Whether they will continue to exempt or they will put and so what percentage they will put, the situation is very, very fluid right now to make any comment. Having said that, we have evaluated our scenario strategy and option. And we have a directional plan in place depending on whatever the outcome of the study and the government of United States makes announcement. We will take a suitable appropriate measure to mitigate the risk whatever best way we can. I think there is no further comments or guidance I can give you because we don't know what the tariffs, if at all, they will be, whether they be 10%, 20%, 25%. There's no clarity on that.

Yes, sure. So -- and the last question, if I may ask, it's on the R&D side. We see that R&D contribution is 5% of the sales. So any guidance like whether this would be the same percent or are we intending to increase? And just where are we attributing -- where are we spending the R&D cost? Just a sense on that.

No. R&D, we are estimating and guiding around the same percentage. Next year also, we will be at around the same percent of 5%. And as you know, all our R&D is split across formulation development for India, ROW and U.S. market. So approximately 50% of the R&D spend is for the U.S. market and rest 50% is for the branded generic business, which is spread across India, Asia and Africa.

Next question is from the line of Dr. Aman Kumar Singh, an individual shareholder.

Congratulations for giving us a good result. But I just also wanted to have a dream. I'm associated with this company right from the IPO days for -- I mean, when we came up in the IPO. Just wanted to know that when we are going to achieve a $1 billion mark as a part of our sales. And similarly, now we have at least one milestone. I can see that we are nearing INR 1,000 crore net profit mark. So when we expect at least $1 billion of sales expectation from my side and at least $250 million of profit from Ajanta Pharma.

These are our aspirations as well. All the growth drivers to make this happen, we work every day very hard to put them in place. We continuously try to identify good products, try to identify newer markets, try to increase the market share in every product. So I think the team is working very hard to see that we continue to propel this growth. I think hopefully, it should come very soon in near future. So that's all we can say about this.

No, the rate at which we are growing, I think this 11%, 12%, 15% of rate of growth will actually lead us to $1 billion mark in not less than another 5 to 6 years' time. So this can be a little -- because if there are other opportunities, what our company can explore and then put some growth drivers into it. So like as you were saying about recent regulations that is happening in U.S. So similarly, they are also coming up -- they are giving boost to CDMO and CDSCO, all those kind of players. So if we can broaden our portfolio base in some way so that we can increase our sales. So like an optimistic view from my side, and I also want our company to achieve it.

Agreed, agreed. No, point noted. Be rest assured, we have a good business development team and as a top management, we are continuously evaluating all the possible opportunities. As you rightly said, if we continue to grow at mid-teens in 5 years, we should 2x business. So we are doing everything to see that. We put all the growth drivers in place. As you rightly said, hopefully, it should happen in 5 to 6 years. It could happen earlier also, who knows.

Next follow-up question is from the line of Tushar Manudhane from Motilal Oswal Financial Service.

Sir, just again on the U.S. business, where the filings has been less in FY '25, while the ramp-up in filings is expected in FY '26, but what is giving the confidence for sort of mid-teens sort of a growth in FY '26 in U.S. Generics business?

So U.S. filing is separate than the growth we are looking at the next year. So yes, I agree with you. Current year, our filing has been slightly less than what would have liked. We have guided 8% to 10% or 8% to 12%. Two of our ANDAs, which were to be -- this thing is getting spilled over. Some studies have not been successful. But I can definitely say that I think 10 ANDAs minimum are for sure looking very, very much possible for the next year, considering the development stage where we are in for the pilot files, which we have passed and all those things go up to 12 also. So we feel very, very comfortable and confident of the next year ANDA filing. And the growth which you are talking for the U.S. business, '25, '26 of high teens is more on the back of 4 launches, which we have done in the last 6 months. The Q3, we did 3 launches and Q4, we did 1 launch. And in next year, we are looking to launch 7 new products. So the last 4 products which we launched in second half, that will ramp up in the current year. And there is some part of the new 7 product launches, which will be scattered over the year. Some upside will get from there. So a combination of this put together, we are giving the guidance of high teens growth in the U.S. market for the next year.

Understood. And sir, just lastly, at the industry level, like any disruption you are witnessing either on the raw material procurement or on the U.S. exports front in anticipation of this geopolitical tariff trade war?

No. Currently, as you know, there is no tariffs on the pharma, except the 20% tariff, which was announced by the U.S. government on China. So that first 20% tariff applies to the pharma also coming from China to the U.S. But other than that, there is no other tariff on the pharma coming into U.S. from any other place. The 20% tariff on pharma, which was first announcement by the U.S. government, we have not seen any kind of things, any shakeup or any disruption or any kind of significant changes or movements because of that. So far, market seems to be pretty much as it was before. There's no shakeups which we have seen.

Next question is from the line of Shrikant Akolkar from Nuvama.

Now my question is on the India business. We have done MR additions. We have done a few launches, and we also have put it in new therapies. So over a 2- to 3-year period, how do you see the India business shaping up?

Well, our primary objective remains to outpace each therapeutic segment that we are present in and operate in. If we are able to outpace the market at a molecule level and at a therapeutic level, I think that's our prime goal. And if the India market is growing at 8% at an IPM level, our aspiration and aim is to grow at least 200 bps faster than the IPM growth. And so that's what -- that's how we can look at for the next 2 years also.

And the new therapies that we have entered, when do you think that those therapies could be contributing substantially, let's say, meaningfully? What could be the, let's say, 3-year, 5-year period where we think this can add meaningful value?

No, it's a good question. Both the therapeutic segments are quite competitive. The competitive intensity is very high. It will take maybe at least 3 years because we have just entered last year with the first-line treatment frank portfolio for each segment. And really to make a presence felt, it will take about 3 years, at least that's what we are aiming for.

Understood. And on the new product acquisitions that we have done, a few products that you have highlighted, is it possible to talk about the thought process that have gone because we have not done any acquisitions so far. So what could have changed? And how big are these products?

So the annual revenue was about INR 15 crores to INR 17 crores for these brands. They were acquired from a company called Axigen. They are primarily into pain management segment. Honestly, the outlook has not changed. We have always been looking out for acquiring good assets, brands or companies in the domestic market. And we have been in the foray in many such acquisitions that have happened and companies that have got sold or acquired. And this brand augmented very well with our current product portfolio. And therefore, we made the acquisition, and we are reasonably confident of having a quick payback and building these brands to a much larger scale than what we acquired them at.

Understood. And on the liquid formulation facility, can you talk more about it? I understand it is expanding substantially at the existing liquid capacity. But when do we think this will commission? And what sort of opportunities it can bring?

So it will be mostly -- we have a small facility at Chikalthana, our liquid facility, which is quite old now, small capacity, and we are doing a lot of contract manufacturing outside. Contract manufacturing has a limitation on how much we can scale up, get the approvals from the various authorities in the emerging markets, audits, so very dependent. And our philosophy and objective of Ajanta Pharma has been to get the production inside as much as we can. So with that outlook, we have put up a new liquid block at Pithampur. So basically, it will be getting all the contract manufacturing inside at our facility and moving some part of the production from Chikalthana to this facility. And this will also act as a platform for us to develop and file new liquid products from this facility into our emerging markets. And going forward in 3, 4 years, then they will be available for us to commercialize. So that's the outlook for the liquid plant.

Okay. And final question, would it be possible to talk about some of the launches that we have done in the U.S. market and maybe some of the market share, if possible?

What exactly you want to know? What is the question you were asking?

So you said that you have launched, I think, 5 to 6 products during the second half of FY '25. Just wanted to know if you can highlight -- as you said, the bigger opportunity for Ajanta will be in the FY '26 when they gain market share. So if you can highlight the name, if possible, of course, name of the product and current market share that we have done there?

Yes. No, so I think we've launched 3, 4 products. We've launched Fluvoxamine ER tablet, then oxcarbazepine, which is Oxtellar, ER. That can become a decent sized product for us in the coming year. So as you know, that when you launch the product, the market shares are small and next 6 months or 8 months, then we become the sizable -- they can become a full-blown opportunity. And there will be 7 new products, which I'm not able to share the names of those products with you, but there will be some good product launches, which will happen next year. All in all, if you see the IQVIA data, wherever Ajanta has launched the product, we have always been one of the top 2 or 3 companies having the market share. Our supply track record is one of the best in the industry. We have a fill rate of 99.9%. So we have no back orders. Our supply chain is one of the most robust supply chain. That enables us -- and the customer then have a confidence when they join hands with us or give orders to us that they can give the product -- they can get the product consistently. So that has been our strong suite, and we will continue to work on that. So all these products -- end of the day whatever price erosion, which happens, which we are estimating into the high single digit plus the new product launches and market share from that, all put together, we are expecting this to give us a high teens growth in the U.S.

Just last question, with your permission, what should be the CapEx next year?

Around INR 300 crores.

INR 300 crores.

Next follow-up question is from the line of Vishal from Systematix.

Sir, with respect to Africa and Asia market, any large markets that we intend to enter this year or the year after?

In Asia and Africa?

Right.

No, Africa, we pretty much are present in most of the countries which are sizable and which can -- where we can scale up. So we are present in pretty much around 18 to 20 countries in Africa. In Asia also, I think we have taken initiative of Central Asia a year or 2 years back. So we are scaling up there. It will take another 2, 3 years for it to become sizable. But other than that, I think we continue with our existing Southeast Asia, Middle East, Central Asia is a new addition. A new addition when I say the last 2 years, but it will still take a few more years for it to become sizable. So that's where our focus is right now.

So basically, with your existing portfolio of markets and filings, can you sustain the growth in Africa and Asia around this low to mid-teens levels for the next maybe 3, 4 years?

Yes, yes. We feel very comfortable. We have a lot of good products under approval in various therapeutic segments in all these markets. So when we get the approval, we can launch them. We have a very good understanding of this market, which enables us to accelerate and get the market share quicker. There are good products which are under R&D right now, which when they get developed, will be manufactured and filed. So there is a robust pipeline awaiting approval for the dossiers filed and under R&D. So there are a lot of therapeutic segments we are not present in these markets where we can enter and get the market share. Like we are not there in gynecology, we are not there in CNS. There are a number of segments. So I think there is enough head space for us to keep growing by adding new products, adding people and increasing the market share from the existing products.

And is it fair to say these markets are even more underpenetrated than what India is, Africa and Asian markets you would be present in with respect to the chronic segments and these new therapies that you talked about, gynecology?

No -- I mean it's a very subjective. Each market has their own curve of growth and evolution. So some markets are very mature like India, CNS is a very large market size. Some markets in Africa may not have such a big market size of CNS now. But in the future -- like India also 15, 20 years back, CNS is very small. Ophthalmic was very small, but now it has become very big. So it's an opportunity for us to kind of enter these segments now when they are small in these markets. And as they keep growing -- because they will post growth which are faster than other segments, which are mature. Mature therapeutic segments will post a growth of 6%, 7%. These segments would post much higher growth of 12%, 15%. So considering the strength which we have, we are one of the unique companies having such a large field size outside of India. So we understand this market much better. So with that strength, we have a good equity with the doctors, and we should be able to get into segments and make a meaningful portfolio out of them.

Got it, sir. And sir, just one final one. We had a 76% payout this year. Should we expect a similar payout going forward?

I mean the only way we can use the money is with the CapEx. We have given INR 300 crores guidance, which is almost the same as current year. Second is acquisition. So if we have any targets for acquisition, the money could be deployed there. If not, then like in the last 2, 3 years, we have given out this money to the shareholders, and we'll give out the money to the shareholders, if there's no acquisition, which comes through.

[Operator Instructions] Next question is from the line of Akash Singhania from Raay Global Investments.

Sir, in one of your previous response, you mentioned that the tariff to U.S. for India is 0 and for China, currently it's 20%. So assuming it continues, I want to understand 2 things. One is for a similar product, what would be generally the difference between the prices of India and China? And secondly, will 20% further tariff on China make Indian products and for us more attractive and competitive to gain market share?

So right now, as you know, there's a 20% tariff on pharma going out from China to U.S., which is not there in any other country. So to that extent, Chinese companies and whatever arrangement they have with their customer, they have to see how they are going to absorb that. We have very few products with the Chinese players overlapping with them. So we don't have any idea on how that is being done. But generally, the sense which we get from the market as there has been not any big shakeup or disruption. So we don't know how that has worked out, whether the prices got passed on, whether the Chinese companies are absorbed. But anyway, I think in the finished product, India is much, much, much larger than the China in the finished formulation. So it depends. Going forward, what is the difference between the tariff between India and China. Going forward, if they put a 25% tariff, will it be common 25% and China will not have that 20% will be removed and they also have 25%, we don't know. So there are a lot of uncertainties to kind of like make a sense and speculate on that.

Okay. So -- but the price differential currently would between, let's say, the Indian formulation and Chinese formulations, maybe for your portfolio of products would be in what range?

No, we don't -- as I told you, we don't have overlap with the competitor from China. [indiscernible] any shake up there.

Okay. And sir, second question is on -- for our total portfolio, how much would be acute and how much chronic?

It differs from market to market actually. So like, for example, if you take India, it is almost about 65% chronic, whereas in emerging markets, overall, if you take, it will be less than 50%.

Okay. Okay. And sir, lastly, we acquired these, I think, 2 or 3 brands, which you mentioned with the revenues of INR 17 crores. Can you share how much amount we have spent on that?

I think it is about INR 40 crores.

Ladies and gentlemen, that was the last question for the day. I would now like to hand the conference over to Mr. Yogesh Agarwal for the closing comments.

Thank you, everyone, for joining this call. In case if there are any other further questions that remain unanswered today, you can reach to our Investor Relations team. Thank you.

Thank you, sir. On behalf of Ajanta Pharma, that concludes this conference. Thank you all for joining us, and you may now disconnect your lines.